Researchers describe GLP-1s reopening 'cultural body trauma' for women

A report from Canberra, Australia describes women feeling that the surge in use of GLP-1 medications such as Ozempic and Mounjaro is reopening old wounds from diet culture, rather than simply offering a new medical option.^[1] Health advocate Yemi Penn told the Australian Associated Press that online chatter about "skinny trending again" has revived judgment about women's bodies that she says she grew up with, including fad diets like the apple cider vinegar trend.^[1] "It's triggered cultural trauma on the female body, and how much we feel we need to have an opinion on it," she said.^[1]

Penn has taken a low dose of a GLP-1 medication for 18 months alongside a fitness plan, and says she believes she has had perimenopause symptoms since her late 30s.^[1] She said the medication helped her eat higher-quality meals without food cravings interfering, and helped her finish a book about understanding her body.^[1] She also said she personally does not feel the stigma around GLP-1 use because of prior work addressing her own trauma, but that she sees the stigma "everywhere" in public conversation.^[1]

Dr. Angela Kwong, a general practitioner quoted in the same report, said most of her female patients who take GLP-1 medications do so for health reasons, including managing fertility issues, pre-diabetes, or perimenopause symptoms, not purely for appearance.^[1] She said talking about weight can make patients uncomfortable because of existing stigma and weight discrimination, especially for people who have tried to manage weight on their own for a long time.^[1] Both women were set to discuss these experiences on a panel at the Women's Health and Wellbeing Summit in Sydney, hosted by Women's Agenda.^[1]

The source material is a news article built around personal interviews and a scheduled panel discussion, not a peer-reviewed or formally published qualitative study. Details such as sample size, research methodology, or an academic institution behind any formal study are not included in the available reporting, so it is not yet known whether a separate academic paper exists describing this pattern in more systematic terms.^[1]

Why it matters for patients

For women in the United States considering or already using semaglutide (Ozempic, Wegovy, Rybelsus) or tirzepatide (Mounjaro, Zepbound), this reporting suggests that decisions about these medications can carry social and emotional weight beyond the physical effects of the drug itself. Both women quoted described weight loss drug use as tied up with years of prior messaging about how women's bodies should look, and said that stigma and judgment remain part of the conversation even when a medication is used for a documented health reason such as pre-diabetes or perimenopause symptoms.^[1]

The account also points to why some patients may feel conflicting pressures: outside judgment about using the drugs at all, alongside separate judgment about body size regardless of medication use. Kwong's comment that patients can feel "uncomfortable" discussing weight because of existing stigma suggests these dynamics can shape conversations patients have with their own doctors, not just online.^[1]

What happens next

Penn and Kwong were scheduled to speak on a panel about these issues at the Women's Health and Wellbeing Summit in Sydney, held by Women's Agenda, on the Tuesday following the report's August 30, 2026 publication.^[1] The source does not indicate whether a formal research paper or study will follow from this discussion, so further peer-reviewed findings on this topic are not yet known.^[1]